Why the study?
Recent reports suggest perioperative use of GLP-1-RAs may increase bronchoaspiration risk despite guideline-compliant fasting, prompting a need to review current evidence, recommendations, and knowledge gaps.
Does the perioperative use of GLP-1-RAs increase the risk of bronchoaspiration in patients undergoing anesthesia?
Does the perioperative use of GLP-1-RAs increase the risk of bronchoaspiration in patients undergoing anesthesia?
Perioperative use of GLP-1-RAs is associated with delayed gastric emptying and a potential increased risk of bronchoaspiration, highlighting the need for specific preoperative fasting and drug cessation guidelines.
May warrant aspiration precautions perioperatively with GLP-1-RAs; leaves open standardized management protocols.
PURPOSE OF REVIEW: To summarize the mechanism of action, clinical outcomes, and perioperative implications of glucagon-like peptide-1 receptor agonists (GLP-1-RAs). Specifically, this review focuses on the available literature surrounding complications (primarily, bronchoaspiration) and current recommendations, as well as knowledge gaps and future research directions on the perioperative management of GLP-1-RAs. RECENT FINDINGS: GLP-1-RAs are known to delay gastric emptying. Accordingly, recent case reports and retrospective observational studies, while anecdotal, suggest that the perioperative use of GLP-1-RAs may increase the risk of bronchoaspiration despite fasting intervals that comply with (and often exceed) current guidelines. As a result, guidelines and safety bulletins have been published by several Anesthesiology Societies. SUMMARY: While rapidly emerging evidence suggests that perioperative GLP-1-RAs use is associated with delayed gastric emptying and increased risk of bronchoaspiration (particularly in patients undergoing general anesthesia and/or deep sedation), high-quality studies are needed to provide definitive answers with respect to the safety and duration of preoperative drug cessation, and optimal fasting intervals according to the specific GLP-1-RA agent, the dose/duration of administration, and patient-specific factors. Meanwhile, clinicians must be aware of the potential risks associated with the perioperative use of GLP-1-RAs and follow the recommendations put forth by their respective Anesthesiology Societies.
No takes yet. Share an insight, caveat, or question.
Mizubuti et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: